• April 22, 2010
Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug "ADI-PEG 20"
• April 17, 2009
Polaris Collaborator to Present Research into ADI-PEG 20's Mechanism of Action at AACR 2009
• January 16, 2009
Advisory Panel Meeting Held in San Francisco: Plans for Phase 3 Trial of ADI-PEG 20 in HCC Patients Discussed
• January 15, 2009
Polaris' ADI-PEG 20 Featured in Cancer Research Article: Novel Treatment for Prostate Cancer
• January 14, 2009
Li-Tzong Chen to Present Results of Completed Asian Phase 2 Clinical Trial of ADI-PEG 20 Treatment for HCC at ASCO Gastrointestinal Cancers Symposium
• December 31, 2008
Polaris Acquires TDW Pharmaceuticals, Inc.
• December 15, 2008
USPTO Issues Notice of Allowance for Polaris' US Protein Kinase Inhibitors Patent
• October 17, 2008
Press Conference Held in Taiwan to Announce the Results of a Phase 2 Trial of ADI-PEG 20 in Advanced HCC
• October 15, 2008
Polaris' ADI-PEG 20 Featured in International Journal of Cancer Article: Novel Treatment for Pancreatic Cancer
• May 28, 2008
Polaris Acquires Equity Stake in EnzymeRx
• August 14, 2007
Ludwig Institute for Cancer Research Initiates Clinical Trial of Polaris' ADI-PEG 20 for the Treatment of Melanoma
• March 30, 2006
Polaris acquires Phoenix Pharmacologics, Inc. Intellectual Property